The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer

International Journal of Oncology

Volumn 37, Issue 4, 2010, Pages 829-835

  Morishita, Asahiro ^a   Gong, Jian ^b   Nomura, Takako ^b   Yoshida, Hirohito ^b   Izuishi, Kunihiko ^b   Suzuki, Yasuyuki ^b   Kushida, Yoshio ^b   Haba, Reiji ^b   D'Armiento, Jeanine ^a   Masaki, Tsutomu ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Colon cancer therapy; Protein array; RTKs

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN TYROSINE KINASE; STRESS ACTIVATED PROTEIN KINASE; TRASTUZUMAB;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SIGNAL TRANSDUCTION; TUMOR GROWTH; XENOGRAFT;

AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CACO-2 CELLS; COLONIC NEOPLASMS; ENZYME ACTIVATION; FEMALE; FLUOROURACIL; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956505966     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000733     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
2. Devine RM and Dozois RR: Surgical management of locally advanced adenocarcinoma of the rectum. World J Surg 16: 486-489, 1992.
3. Izbicki JR, Hosch SB, Knoefel WT, Passlick B, Bloechle C and Broelsch CE: Extended resections are beneficial for patients with locally advanced colorectal cancer. Dis Colon Rectum 38: 1251-1256, 1995.
4. Wang Y, Cummings B, Catton P, et al: Primary radical external beam radiotherapy of rectal adenocarcinoma: long term outcome of 271 patients. Radiother Oncol 77: 126-132, 2005.
5. Robertson SC, Tynan J and Donoghue DJ: RTK mutations and human syndromes: when good receptors turn bad. Trends Genet 16: 368, 2000.
6. Robinson DR, Wu YM and Lin SF: The protein tyrosine kinase family of the human genome. Oncogene 19: 5548-5557, 2000.
7. Becker JC, Muller-Tidow C, Serve H, Domschke W and Pohle T: Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 12: 3297-3305, 2006. (Pubitemid 43933772)
8. Prenzel N, Zwick E, Leserer M and Ullrich A: Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res 2: 184-190, 2000.
9. Tanner M, Hollmen M, Junttila TT, et al: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278, 2005.
10. Svensson S, Jirstrom K, Ryden L, et al: ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 24: 4370-4379, 2005.
11. Shawver LK, Slamon D and Ullrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1: 117-123, 2002.
12. Cao C, Albert JM, Geng L, et al: Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res 66: 11409-11415, 2006. (Pubitemid 46009972)
13. Marmor MD, Skaria KB and Yarden Y: Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58: 903-913, 2004.
14. Dursun A, Poyraz A, Suer O, Sezer C and Akyol G: Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia. Pathol Oncol Res 7: 24-27, 2001.
15. Ross JS and McKenna BJ: The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 19: 554-568, 2001. (Pubitemid 32619394)
16. Mann M, Sheng H, Shao J, et al: Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120: 1713-1719, 2001.
17. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM and Ullrich A: p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165-1172, 1989.
18. Austin CD, De Maziere AM, Pisacane PI, et al: Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15: 5268-5282, 2004.
19. Hommelgaard AM, Lerdrup M and van Deurs B: Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 15: 1557-1567, 2004.
20. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127-137, 2002.
21. Hynes NE and Dey JH: PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough. Cancer Cell 15: 353-355, 2009.
22. Junttila TT, Akita RW, Parsons K, et al: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15: 429-440, 2009.
23. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM and Hynes NE: ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 20: 3210-3223, 2000.
24. Lee H, Akita RW, Sliwkowski MX and Maihle NJ: A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res 61: 4467-4473, 2001. (Pubitemid 32685776)
25. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127, 2004.
26. Masaki T, Tokuda M, Yoshida S, et al: Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver. Int J Oncol 26: 661-671, 2005.
27. Yoshida S, Masaki T, Feng H, et al: Enhanced expression of adaptor molecule p46 Shc in nuclei of hepatocellular carcinoma cells: study of LEC rats. Int J Oncol 25: 1089-1096, 2004.
28. Yukimasa S, Masaki T, Yoshida S, et al: Enhanced expression of p46 Shc in the nucleus and p52 Shc in the cytoplasm of human gastric cancer. Int J Oncol 26: 905-911, 2005.
29. Friedlander E, Barok M, Szollosi J and Vereb G: ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunol Lett 116: 126-140, 2008.
30. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
31. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER- 2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
32. Kavanagh DO, Chambers G, O'Grady L, et al: Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 9: 1, 2009.
33. Kuwada SK, Scaife CL, Kuang J, et al: Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. Int J Cancer 109: 291-301, 2004.
34. Sartor CI: Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin Radiat Oncol 13: 22-30, 2003.
35. Shin EY, Lee BH, Yang JH, et al: Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer. J Cancer Res Clin Oncol 126: 519-528, 2000.
36. Zhang Y, Zhang J, Lin Y, et al: Role of epithelial cell fibroblast growth factor receptor substrate 2alpha in prostate development, regeneration and tumorigenesis. Development 135: 775-784, 2008.
37. Cetta F, Chiappetta G, Melillo RM, et al: The ret/ptc1 oncogene is activated in familial adenomatous polyposis-associated thyroid papillary carcinomas. J Clin Endocrinol Metab 83: 1003-1006, 1998. (Pubitemid 28496483)
38. Oki M, Yamamoto H, Taniguchi H, Adachi Y, Imai K and Shinomura Y: Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers. World J Gastroenterol 14: 5650-5656, 2008.
39. Iiizumi M, Hosokawa M, Takehara A, et al: EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth. Cancer Sci 97: 1211-1216, 2006.
40. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM and Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26: 60-70, 1999.
41. Cuello M, Ettenberg SA, Clark AS, et al: Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61: 4892-4900, 2001.
42. Mitchell MS: Immunotherapy as part of combinations for the treatment of cancer. Int Immunopharmacol 3: 1051-1059, 2003. (Pubitemid 36830850)
43. Mitchell MS: Combinations of anticancer drugs and immunotherapy. Cancer Immunol Immunother 52: 686-692, 2003.
44. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.